Cargando…

Rare occurence of amennorrhea associated with olanzapine : a case report

INTRODUCTION: Amenorrhea secondary to hyperprolactinemia is one of the frequent adverse effects associated with the use of atypical antipyschotics. It is often neglected but can interrupt the compliance of treatment. Several studies indicate that olanzapine does not significantly affect serum prolac...

Descripción completa

Detalles Bibliográficos
Autores principales: Khivsara, A., Goya, D., Nebhinani, N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9568074/
http://dx.doi.org/10.1192/j.eurpsy.2022.1848
_version_ 1784809557831188480
author Khivsara, A.
Goya, D.
Nebhinani, N.
author_facet Khivsara, A.
Goya, D.
Nebhinani, N.
author_sort Khivsara, A.
collection PubMed
description INTRODUCTION: Amenorrhea secondary to hyperprolactinemia is one of the frequent adverse effects associated with the use of atypical antipyschotics. It is often neglected but can interrupt the compliance of treatment. Several studies indicate that olanzapine does not significantly affect serum prolactin levels in the long term, although contrary has been observed in few case reports. OBJECTIVES: To report a case of olanzapine-induced amenorrhea due to hyperprolactinemia. METHODS: A 27-year-old woman with history of stillbirth 5 months prior, presented to OPD with hallucinatory behaviour and socio-occupational dysfunction for 5 months. She was on tianeptine 12.5 mg, escitalopram 10 mg and alprazolam 0.5 mg at presentation and was having regular menses. On assessment, she was diagnosed with unspecified psychosis. Her ongoing medications were stopped and she was started on Olanzapine (optimized to 20 mg/day) after which she reported significant improvement however developed amenorrhea within next 2 months hence advised to consult Obgyn. Urine pregnancy test came out negative and prolactin level was found to be 64.2 ng/ml. Other investigations including MRI were within normal limit. Olanzapine was cross tapered with Aripiprazole (maintained at 10 mg/day). Clonazepam was advised SOS for anxiety. RESULTS: After 1 month of aripiprazole treatment, monthly menses resumed and prolactin level returned to normal range. No biological dysfunction or other side effects were reported by the patient. CONCLUSIONS: Olanzapine-induced amennorhea secondary to hyperprolactinemia, is a rare but possible event. We report a case in which olanzapine induced amenorrhea normalized after switching to aripiprazole. Baseline prolactin level should be obtained as they help in the management of patients with neuroleptic-induced hyperprolactinemia. DISCLOSURE: No significant relationships.
format Online
Article
Text
id pubmed-9568074
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Cambridge University Press
record_format MEDLINE/PubMed
spelling pubmed-95680742022-10-17 Rare occurence of amennorrhea associated with olanzapine : a case report Khivsara, A. Goya, D. Nebhinani, N. Eur Psychiatry Abstract INTRODUCTION: Amenorrhea secondary to hyperprolactinemia is one of the frequent adverse effects associated with the use of atypical antipyschotics. It is often neglected but can interrupt the compliance of treatment. Several studies indicate that olanzapine does not significantly affect serum prolactin levels in the long term, although contrary has been observed in few case reports. OBJECTIVES: To report a case of olanzapine-induced amenorrhea due to hyperprolactinemia. METHODS: A 27-year-old woman with history of stillbirth 5 months prior, presented to OPD with hallucinatory behaviour and socio-occupational dysfunction for 5 months. She was on tianeptine 12.5 mg, escitalopram 10 mg and alprazolam 0.5 mg at presentation and was having regular menses. On assessment, she was diagnosed with unspecified psychosis. Her ongoing medications were stopped and she was started on Olanzapine (optimized to 20 mg/day) after which she reported significant improvement however developed amenorrhea within next 2 months hence advised to consult Obgyn. Urine pregnancy test came out negative and prolactin level was found to be 64.2 ng/ml. Other investigations including MRI were within normal limit. Olanzapine was cross tapered with Aripiprazole (maintained at 10 mg/day). Clonazepam was advised SOS for anxiety. RESULTS: After 1 month of aripiprazole treatment, monthly menses resumed and prolactin level returned to normal range. No biological dysfunction or other side effects were reported by the patient. CONCLUSIONS: Olanzapine-induced amennorhea secondary to hyperprolactinemia, is a rare but possible event. We report a case in which olanzapine induced amenorrhea normalized after switching to aripiprazole. Baseline prolactin level should be obtained as they help in the management of patients with neuroleptic-induced hyperprolactinemia. DISCLOSURE: No significant relationships. Cambridge University Press 2022-09-01 /pmc/articles/PMC9568074/ http://dx.doi.org/10.1192/j.eurpsy.2022.1848 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstract
Khivsara, A.
Goya, D.
Nebhinani, N.
Rare occurence of amennorrhea associated with olanzapine : a case report
title Rare occurence of amennorrhea associated with olanzapine : a case report
title_full Rare occurence of amennorrhea associated with olanzapine : a case report
title_fullStr Rare occurence of amennorrhea associated with olanzapine : a case report
title_full_unstemmed Rare occurence of amennorrhea associated with olanzapine : a case report
title_short Rare occurence of amennorrhea associated with olanzapine : a case report
title_sort rare occurence of amennorrhea associated with olanzapine : a case report
topic Abstract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9568074/
http://dx.doi.org/10.1192/j.eurpsy.2022.1848
work_keys_str_mv AT khivsaraa rareoccurenceofamennorrheaassociatedwitholanzapineacasereport
AT goyad rareoccurenceofamennorrheaassociatedwitholanzapineacasereport
AT nebhinanin rareoccurenceofamennorrheaassociatedwitholanzapineacasereport